DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Apokyn (Apomorphine Hydrochloride) - Summary

 
 



APOKYN SUMMARY

APOKYN™ (apomorphine hydrochloride, USP) is a non-ergoline dopamine agonist.

APOKYN™ (apomorphine hydrochloride injection) is indicated for the acute, intermittent treatment of hypomobility, "off" episodes ("end-of-dose wearing off" and unpredictable "on/off" episodes) associated with advanced Parkinson's disease. APOKYN has been studied as an adjunct to other medications (see CLINICAL PHARMACOLOGY: Clinical Trials).


See all Apokyn indications & dosage >>

NEWS HIGHLIGHTS

Media Articles Related to Apokyn (Apomorphine)

α-Synuclein Mutant Mice Display Parkinson's Disease-Like Sleep And Motor Problems
Source: Anxiety / Stress News From Medical News Today [2013.06.11]
The presence of Lewy bodies in nerve cells, formed by intracellular deposits of the protein α-synuclein, is a characteristic pathologic feature of Parkinson's Disease (PD). In the quest for an animal model of PD that mimics motor and non-motor symptoms of human PD, scientists have developed strains of mice that overexpress α-synuclein...

Multiple Sclerosis, Parkinson's Disease And Muscular Degeneration Could Be Impacted By Stem Cell Study
Source: Multiple Sclerosis News From Medical News Today [2013.06.05]
Scientists have taken a vital step forward in understanding how cells from skin tissue can be reprogrammed to become stem cells. New research could pave the way to generate these stem cells efficiently to better understand and develop treatments for diseases such as multiple sclerosis, Parkinson's disease and muscular degeneration...

Incurable Neurological Disorder HDLS Often Incorrectly Diagnosed As Alzheimer's Disease, MS Or Parkinson's Disease
Source: Multiple Sclerosis News From Medical News Today [2013.04.13]
The very serious hereditary disease HDLS was discovered in 1984 in Sweden. Many HDLS patients are still incorrectly diagnosed with Alzheimer's disease, MS or Parkinson's disease, but researchers at the Sahlgrenska Academy, University of Gothenburg, Sweden, have now developed a more certain diagnosis method - and are seeking to find a treatment for the "unknown" neurological disorder...

Key Initiator To Prion And Parkinson's Disease Is Likely Brain Inflammation
Source: CJD / vCJD / Mad Cow Disease News From Medical News Today [2012.12.03]
Prion diseases represent a family of neurodegenerative disorders associated with the loss of brain cells and caused by proteins called prions (derived from 'protein' and 'infection'). The diseases are found in both humans and animals, such as Creutzfeld-Jakob disease and mad cow disease respectively...

Parkinson's Disease Quiz: Test Your Medical IQ
Source: MedicineNet amantadine Specialty [2011.08.31]
Title: Parkinson's Disease Quiz: Test Your Medical IQ
Category: MedicineNet Quiz
Created: 8/23/2011 12:53:00 PM
Last Editorial Review: 8/31/2011 2:27:29 PM

more news >>

Published Studies Related to Apokyn (Apomorphine)

Apomorphine effect on pain threshold in Parkinson's disease: a clinical and positron emission tomography study. [2011.01]
Patients with Parkinson's disease (PD) frequently experience pain that could be in part due to central modification of nociception. In this randomized controlled double blind study, we compared the effect of apomorphine versus placebo on pain thresholds and pain-induced cerebral activity in 25 patients with PD...

Comparison of apomorphine and levodopa infusions in four patients with Parkinson's disease with symptom fluctuations. [2009.05]
BACKGROUND: Motor fluctuations in patients with advanced Parkinson's disease may be successfully treated with subcutaneous apomorphine infusion or intraduodenal levodopa/carbidopa infusion. No comparative trials of these two alternatives were performed. AIMS OF THE STUDY: We present a subanalysis from a randomized crossover clinical trial where levodopa infusion as monotherapy was compared with any other combination of pharmacotherapy in fluctuating patients. Four patients used apomorphine infusion and oral levodopa in the comparator arm. The results of these four patients are presented in detail... CONCLUSIONS: Monotherapy with duodenal infusion of levodopa was more efficacious and brought greater QoL than combination therapy with apomorphine infusion in these fluctuating patients.

Apomorphine nodules in Parkinson's disease: best practice considerations. [2008.10]
Apomorphine hydrochloride infusion therapy is used by approximately 1000 people with advanced Parkinson's disease in the UK (Britannia Pharmaceuticals Ltd, 2008).

Comparative cross-over study of sildenafil and apomorphine for treating erectile dysfunction. [2008.09]
OBJECTIVE: To compare the effectiveness, safety and tolerability of sildenafil and apomorphine in Brazilian patients with erectile dysfunction (ED) of various causes... CONCLUSIONS: Sildenafil is more effective than apomorphine for treating ED, in the domains of erectile function, satisfaction with sexual intercourse and overall satisfaction, and was the drug preferred by most of the patients.

Apomorphine for the acute treatment of "off" episodes in Parkinson's disease. [2008.03]
Many patients with advanced Parkinson's disease (PD) experience motor complications, which negatively impact quality of life, despite optimized oral therapy.

more studies >>

Clinical Trials Related to Apokyn (Apomorphine)

Apokyn for Motor IMProvement of Morning AKinesia Trial (AM IMPAKT) [Recruiting]

Comparison of Continuous and Pulsatile Apomorphine in Parkinson's Disease [Recruiting]
The purpose of this study is to compare the effects of apomorphine, given by two different methods, to determine how best to manage dyskinesias.

Safety/Efficacy of Tigan� to Control Nausea/Vomiting Experienced During Apokyn� Initiation and Treatment [Recruiting]
The purposes of the study are to determine:

i. To assess the efficacy of Tigan® (trimethobenzamide) in preventing nausea and vomiting when initiating therapy with Apokyn® (apomorphine)

ii. To determine the optimal duration for continuation of Tigan® following initiation of Apokyn® therapy

iii. To assess the safety of Tigan® in combination with Apokyn®

iv. To characterize the pharmacokinetic (PK) profile of apomorphine in subjects treated concomitantly with and without Tigan®

Relationship Between D2 Receptors SPECT and the Apomorphine Test in Patients With OH Dependence (ALC-DRD2-APO) [Recruiting]
OH dependence is associated with DA receptor changes. Both, the apomorphine test and the D2Rec SPECt are usefull for monitoring DA receptor status. We aimed at studying whether DA receptor hypofunction, assessed by means of the apomorphine test and the D2Rec SPECT, is a marker of relapse in detoxified OH dependents patients.

Efficacy of Continuous Apomorphine Infusion on Cognitive and Neuropsychological Functions in Parkinson's Disease [Recruiting]
In Parkinson's disease, treatment mainly aims to improve motor functions. However, other dysfunctions are often observed in Parkinson's patients, and may have important consequences on the quality of life of patients.

Cognitive and neuropsychological troubles may be observed, as memory impairment or anxiety for example. As this kind of troubles is worrying for the patient himself (herself) and his/her family, treatment needs to take into account those troubles in addition to motor difficulties. In our centre, we have already used continuous Apomorphine infusions among Parkinson's patients and it seems to have good results. The present study aims to objectively assess the efficacy of continuous Apomorphine infusions on cognitive and neuropsychological functions in Parkinson's disease using clinical and positron emission tomography (PET)-scan measures.

more trials >>

Reports of Suspected Apokyn (Apomorphine) Side Effects

Fall (4)Pruritus (2)Erythema (2)Somnolence (2)Malaise (2)Overdose (2)Dyspnoea (2)Condition Aggravated (2)Atrial Fibrillation (2)Malabsorption From Injection Site (2)more >>


Page last updated: 2013-06-11

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2012